NR3C2 and type 2 diabetes mellitus: An actuarial survival analysis estimated the lifetime benefit of SGLT2i, GLP-1RA and nonsteroidal mineralocorticoid receptor agonist (ns-MRA) in people with T2D and albuminuria and found that combination therapy had the lowest hazard ratio of adverse CV and kidney events [42].